2017 News Releases

2017 News Releases

CSL and Vitaeris Announce Strategic Partnership with Option to Acquire
05 Dec 2017

The two companies have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection.

Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
29 Oct 2017

A subgroup analysis of data from the Phase III COMPACT trial showed 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week while on placebo

New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
24 Oct 2017

- HAEGARDA is the first and only subcutaneous preventive treatment option for HAE in the US
- Oral presentation will highlight the preventive effect of HAEGARDA in HAE patients with a high frequency of attacks

CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same
12 Oct 2017

There are more than 350,000 cardiac arrests annually in the U.S.; nearly 90 percent are fatal but when CPR is administered immediately, chances of survival can triple.

Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Disorders
28 Sep 2017

CSL Behring’s LEAD grant is helping them advocate more effectively in a shifting health care environment.

Japan’s Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment
28 Sep 2017

AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat hemophilia A

CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State
19 Sep 2017

CSL Behring commits $4.92 million to Penn State's multidisciplinary Center of Excellence in Biotechnology

CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI
14 Sep 2017

Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives

CSL Behring Presents New Alpha 1 Antitrypsin Deficiency Treatment Data at Global ERS Congress
07 Sep 2017

- Symposium “Transitioning Clinical Data into Patient Care – Recent Real-Life Experiences with Alpha 1”
- RAPID and RAPID extension trial data to be featured in poster and oral presentations

CSL Behring Joins Together With Others Around the World—Sponsoring the 2017 Meeting of the European Society for Immunodeficiencies (ESID)
06 Sep 2017

Biotherapeutics leader to map attendee visits to result in a donation to International Patient Organisation for Primary Immunodeficiencies (IPOPI)

HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
25 Jul 2017

- First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients
- Comprehensive support program offered to patients

CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])
21 Jul 2017

FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks

FDA Accepts CSL Behring’s Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
19 Jul 2017

For the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Hemophilia B
12 Jul 2017

Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product’s impact on treatment adherence, consumption and quality of life

CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
11 Jul 2017

CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards

New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A
10 Jul 2017

Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017

New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017
06 Jul 2017

New findings demonstrate CSL Behring’s promise to develop and deliver innovative treatments that improve patients’ lives

FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema
23 Jun 2017

- HAEGARDA has been shown to reduce HAE attacks by 95 percent (median) in patients with a life-threatening, rare genetic disorder
- Use of rescue medication was reduced by greater than 99 percent (1)
- Subcutaneous administration builds and maintains steady-state C1-INH levels